Loading…
Viridian Therapeutics, Inc. is projected to rise to $20.01 by 2027, a +16% move from its current price of $17.26. VRDN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $16.69 | $17.27 | $17.88 | +0.08% |
| May 30 | $16.46 | $17.29 | $18.16 | +0.17% |
| May 31 | $16.30 | $17.30 | $18.37 | +0.25% |
| Jun 1 | $16.16 | $17.32 | $18.56 | +0.34% |
| Jun 2 | $16.04 | $17.33 | $18.73 | +0.42% |
| Jun 3 | $15.94 | $17.35 | $18.88 | +0.51% |
| Jun 4 | $15.84 | $17.36 | $19.03 | +0.59% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.84 | $17.36 | $19.03 | +0.59% |
| Week 2 | $15.35 | $17.47 | $19.88 | +1.19% |
| Week 3 | $14.99 | $17.57 | $20.58 | +1.79% |
| Week 4 | $14.72 | $17.67 | $21.22 | +2.39% |
| Week 5 | $14.49 | $17.78 | $21.81 | +3.00% |
| Week 6 | $14.29 | $17.88 | $22.37 | +3.61% |
| Week 7 | $14.12 | $17.99 | $22.91 | +4.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression.
The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Viridian Therapeutics, Inc. (VRDN) is a healthcare stock.
The stock's current price is $17.24 and its market cap is $1.9B, with a rank of 2036.
Forecasts imply a rising price trajectory across the coming years, with a 2026 average price of $17.24 and higher averages in subsequent years, including $20.31 in 2027 and $30.17 in 2030.
Beyond 2030 the forecast continues higher, with 2040 average $55.81 and 2050 average $114.54, representing a bullish long-term potential.
A major floor 36.3% below — a decisive break under it would weaken the trend.
The nearest floor, 22.9% below — buyers have tended to step in here.
The nearest ceiling, 8.6% above — a clean break opens room to run.
A major ceiling 94.8% above — clearing it would confirm fresh momentum.
Key VRDN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VRDN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.36 | Sell | $17.16 | Buy |
| MA 10 | $17.02 | Buy | $16.98 | Buy |
| MA 20 | $16.42 | Buy | $16.75 | Buy |
| MA 50 | $17.99 | Sell | $18.62 | Sell |
| MA 100 | $24.23 | Sell | $21.42 | Sell |
| MA 200 | $24.32 | Sell | $22.37 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.96 | Neutral |
| Stoch RSI (14) | 72.63 | Neutral |
| CCI (20) | 45.98 | Neutral |
| Williams %R (14) | -25.00 | Info |
| MACD (12,26,9) | 0.28 | Buy |
| ROC (12) | 3.91 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 75.00 | Neutral |
| TRIX (15) | -0.19 | Sell |
| Awesome (5,34) | 1.73 | Buy |
| Ultimate (7,14,28) | 54.20 | Neutral |
| Momentum (10) | 0.40 | Buy |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 17.44 | Sell |
| ADX (14) | 17.48 | Neutral |
| ATR (14) | 0.60 | Info |
The 30-day picture is Neutral with RSI 14 at 50.
The 50-day moving average sits at $18.46 and the 200-day moving average at $24.31, suggesting near-term upside potential but longer-term headwinds.
Key levels of note are support at $13.30 and resistance at $18.75, while the 30-day range spans $13.55 to $21.93.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.30 | $17.26 | $23.91 | 0% | Neutral | |
| $15.46 | $20.01 | $27.66 | +16% | Neutral | |
| $18.69 | $25.06 | $36.18 | +45% | Bullish | |
| $21.48 | $29.67 | $44.34 | +72% | Bullish | |
| $20.85 | $29.58 | $45.49 | +71% | Bullish | |
| $20.89 | $30.38 | $47.91 | +76% | Bullish | |
| $20.79 | $30.94 | $49.90 | +79% | Bullish | |
| $20.72 | $31.51 | $51.86 | +83% | Bullish | |
| $24.97 | $38.77 | $65.00 | +125% | Bullish | |
| $27.42 | $43.44 | $74.10 | +152% | Bullish | |
| $31.58 | $54.88 | $100.60 | +218% | Bullish | |
| $54.98 | $112.74 | $229.29 | +553% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $13.30 | $17.26 | $20.29 | +0.00% |
| June 2026 | $14.96 | $17.67 | $21.44 | +2.36% |
| July 2026 | $15.61 | $18.64 | $23.01 | +5.51% |
| August 2026 | $15.47 | $18.62 | $23.28 | -0.08% |
| September 2026 | $15.27 | $18.51 | $23.39 | -0.59% |
| October 2026 | $15.78 | $19.25 | $24.56 | +4.00% |
| November 2026 | $15.81 | $19.41 | $24.96 | +0.78% |
| December 2026 | $14.95 | $18.45 | $23.91 | -4.92% |
Click any year to see its month-by-month VRDN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, VRDN is projected to trade between $13.30 and $23.91, averaging $17.26 — a potential gain of 0% from today's $17.26. A consolidation phase looks the most probable path here.
Viridian Therapeutics, Inc.'s 2027 outlook centres on $20.01, within a $15.46 to $27.66 range. That is up +16% on the projected 2026 average. That marks a +16% change versus current levels. Price action looks broadly range-bound.
By 2028, VRDN could reach as high as $36.18, with a base case around $25.06 and support toward $18.69 — roughly +45% from $17.26. Buyers look set to stay in control over this stretch.
Expect VRDN to range from $21.48 to $44.34 through 2029. The $29.67 average target implies a +72% move from current prices. That is up +18% on the projected 2028 average. Momentum favours further upside here.
The VRDN price prediction for 2030 points to an average of $29.58 (low $20.85, high $45.49) — a potential gain of +71% on today's $17.26. Buyers look set to stay in control over this stretch.
In 2031, VRDN is projected to trade between $20.89 and $47.91, averaging $30.38 — a potential gain of +76% from today's $17.26. That is up +3% on the projected 2030 average. Momentum favours further upside here.
Viridian Therapeutics, Inc.'s 2032 outlook centres on $30.94, within a $20.79 to $49.90 range. That is up +2% on the projected 2031 average. That marks a +79% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, VRDN could reach as high as $51.86, with a base case around $31.51 and support toward $20.72 — roughly +83% from $17.26. Momentum favours further upside here.
Expect VRDN to range from $24.97 to $65.00 through 2034. The $38.77 average target implies a +125% move from current prices. That is up +23% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The VRDN price prediction for 2035 points to an average of $43.44 (low $27.42, high $74.10) — a potential gain of +152% on today's $17.26. Momentum favours further upside here.
In 2040, VRDN is projected to trade between $31.58 and $100.60, averaging $54.88 — a potential gain of +218% from today's $17.26. That is up +26% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Viridian Therapeutics, Inc.'s 2050 outlook centres on $112.74, within a $54.98 to $229.29 range. That is up +105% on the projected 2040 average. That marks a +553% change versus current levels. Momentum favours further upside here.
Investing $1,000 in VRDN today (≈ 57.937428 VRDN) could be worth
$6,531.67
+$5,531.67 (+553%) by 2050 · US Dollar
Based on the average projected VRDN price of $112.74 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VRDNwould be worth at today's price.
$1,000 invested in VRDN on May 27, 2025 (≈ 71.787507 VRDN) would be worth
$1,239.05
+$239.05 (+23.9%) today · 1.24× · US Dollar
Based on a VRDN entry price of $13.93 vs. today's $17.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.63 | $979.01 | -2.1% |
| 1 month ago | $13.5 | $1,278.52 | +27.9% |
| 3 months ago | $29.49 | $585.28 | -41.5% |
| 6 months ago | $31.96 | $540.05 | -46.0% |
| 1 year ago | $13.93 | $1,239.05 | +23.9% |
| All time (5.0y) ago | $17.45 | $989.11 | -1.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VRDN forecast.
Our base-case forecast reaches $35.00 around 2034.
Implied market cap at $35.00: $3.86B
The multi-year forecast shows a bullish trajectory. In 2026 the average is $17.24 with a min of $13.30 and a max of $23.90 (ROI 0%). In 2027 the average is $20.31 with a min of $15.57, a max of $28.35 and ROI of 17.8%.
In 2028 the average is $25.41 (min $18.76, max $37.12, ROI 47.4%). In 2029 the average is $30.11 (min $21.54, max $45.58, ROI 74.7%), and 2030 the average is $30.17 (min $20.97, max $47.05, ROI 75%). The forecast continues with 2031 average $30.58 (min $20.70, max $48.95, ROI 77.3%), 2032 average $31.21 (min $20.62, max $51.14, ROI 81%), and 2033 average $32.06 (min $20.69, max $53.65, ROI 86%).
By 2034 the average rises to $39.27 (min $24.78, max $67.00, ROI 127.8%) and by 2035 the average is $44.25 (min $27.33, max $76.87, ROI 156.7%). The 2040 forecast shows an average of $55.81 (min $31.18, max $104.45, ROI 223.7%), and by 2050 the average is $114.54 (min $53.37, max $238.64, ROI 564.4%).
Tap a question to reveal the answer.
The 2030 forecast shows min $20.97, avg $30.17, max $47.05, with ROI 75%.
Forecasts show a bullish trajectory with rising averages and ROIs across the years, including avg $30.17 in 2030 and avg $114.54 in 2050, but these are estimates and not guarantees.
Yes, the max in 2050 is $238.64 and the 2050 avg is $114.54, indicating potential to surpass $100 within the forecast horizon.
Current price is $17.24 and market cap is $1.9B.
Sentiment is NEUTRAL; RSI14 is 50; SMA50 is $18.46; SMA200 is $24.31; support is $13.30; resistance is $18.75; the 30-day range is $13.55 to $21.93.
Viridian Therapeutics, Inc. Community Discussion
0Share your Viridian Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.